Longevity.Technology’s dedicated platform for longevity investors: now approved for USA, UK and other qualifying investing countries
The investment portal is for accredited investors such as venture capitalists, institutional investors, family offices, high net worth and super high net worth investors.
If you are interested in joining other smaller investors in participating in longevity deals (alongside VCs, family offices and other accredited investment firms) we’ll be launching our SPV (special purpose vehicle) service shortly: you can register your interest here.
Longevity.Technology: The longevity sector is rapidly emerging as one of the hottest new investment markets, attracting top investors like Christian Angermayer and Jeff Bezos, firms like Andreessen Horowitz, Sequoia Capital, and Bold Capital Partners, as well as the VC arms of big pharma. We spoke to Longevity.Technology CEO & Founder Phil Newman about what makes longevity such a great investment opportunity.
Newman has long been convinced that longevity needed to make the shift from a movement into an industry, and it was this belief that led him to start Longevity.Technology.
“I felt there was an opportunity to address both the scientific and commercial progress that was starting to happen to build confidence with investors and help those in the sector feel that they were part of something defined,” he says. “We launched Longevity.Technology in September 2019. Since then, we’ve grown quickly, and our ambition now is to really help the sector grow by facilitating investment in it.”
Longevity investment to double in 2022
Newman points out that investment activity in longevity is picking up rapidly.
“In 2021, the $3.8bn invested into longevity was more than double the investment in 2020,” he says. “With $4.1bn already invested into longevity businesses in 2022, and despite the corrections we are seeing in venture markets, we expect this year’s numbers will see another big increase over 2021.”
Longevity venture capital investment ($M)
With the platform going live today, Newman says that details of new deals on the platform will be announced in the days ahead.
“We’ve got some really interesting and exciting opportunities to share with investors,” he says. “We’ve got a cutting-edge diagnostics company and a brain health technology ready to roll, plus many more! We have been very keen to open-up to US investors and I’m delighted to say that we’re now cleared to do this.”
To support investors with more than just deal opportunities, Longevity.Technology’s market intelligence unit is deeply analysing 500 longevity-specific companies
“The datasets we’re building identify the specific longevity domains and investment traction these companies are making – this gives us a unique advantage to identify serious longevity companies and build relationships with investors,” says Newman. “The longevity market is set for explosive growth: the business opportunity in longevity has already started. Everyone is getting very excited about cellular reprogramming and rejuvenation – we’re analysing these new longevity areas to educate the market help get more exciting longevity companies funded.”Investing in early-stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. First Longevity is targeted exclusively at sophisticated investors who understand these risks and make their own investment decisions. Investment opportunities have not been approved as financial promotions and are not covered by the Financial Services Compensation Scheme (FSCS) and you may not have access to the Financial Ombudsman Service (FOS). If you are in any doubt about the action you should take or the contents of any of the Financial Promotion received, you should contact your stockbroker, solicitor, accountant, bank manager or other professional adviser authorised under the Financial Services and Markets Act 2000, who specialises in advising on bonds, shares and other securities, including unlisted securities. Past performance is not a reliable indicator of future performance. You should not rely on any past performance as a guarantee of future investment performance. Tax relief depends on an individual’s circumstances and may change in the future. In addition, the availability of tax relief depends on the company invested in maintaining its qualifying status.
Any financial promotions materials have been approved for financial promotion purposes by Prospect Capital Ltd, which is authorised and regulated in the UK by the FCA reg: 515599